Trial Profile
A first-in-men proof of concept study of SAAP-148
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 11 Sep 2018
Price :
$35
*
At a glance
- Drugs SAAP 148 (Primary)
- Indications Burn infections; Diabetic foot ulcer; Methicillin-resistant Staphylococcus aureus infections; Wound infections
- Focus Adverse reactions; First in man; Proof of concept
- 11 Sep 2018 New trial record
- 27 Aug 2018 According to a Madam Therapeutics media release, the trial will initiate early in 2019.